Micron signs new research agreement with commercial partner

ATLANTA, July 23, 2018 – Following the successful completion of a first stage of preclinical development work with one of its commercial partners, a leading clinical stage biotechnology company, Micron Biomedical, Inc. (Micron) signed a new research agreement (RA) with its partner to continue the development of a microneedle patch for delivery of the partner’s API. The new RA includes additional patch design development work as well as in-vitro and in-vivo evaluation of the microneedle patch. The terms of the RA are confidential.